<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: could differ", fill: "#5d3954"},
{source: "6: could differ", target: "6: materially from", fill: "#5d3954"},
{source: "6: materially from", target: "6: product candidates", fill: "#5d3954"},
{source: "6: product candidates", target: "6: at early stages", fill: "#5d3954"},
{source: "6: at early stages", target: "6: successfully", fill: "#5d3954"},
{source: "6: successfully", target: "6: commercialize them", fill: "#5d3954"},
{source: "6: commercialize them", target: "6: sufficient revenues", fill: "#5d3954"},
{source: "6: sufficient revenues", target: "6: operations", fill: "#5d3954"},
{source: "6: could differ", target: "7: candidates", fill: "#c8a2c8"},
{source: "7: candidates", target: "7: development", fill: "#c8a2c8"},
{source: "7: candidates", target: "16: additional capital outlays", fill: "#e3ff00"},
{source: "16: additional capital outlays", target: "16: expenditures over", fill: "#e3ff00"},
{source: "16: expenditures over", target: "16: next several years as", fill: "#e3ff00"},
{source: "16: next several years as", target: "16: hire additional employees", fill: "#e3ff00"},
{source: "16: hire additional employees", target: "16: preclinical development manufacturing", fill: "#e3ff00"},
{source: "16: preclinical development manufacturing", target: "16: clinical trial", fill: "#e3ff00"},
{source: "16: clinical trial", target: "16: activities", fill: "#e3ff00"},
{source: "16: additional capital outlays", target: "23: additional", fill: "#fff700"},
{source: "23: additional", target: "23: collaboration", fill: "#fff700"},
{source: "23: collaboration", target: "23: arrangements", fill: "#fff700"},
{source: "23: arrangements", target: "23: relinquish", fill: "#fff700"},
{source: "23: relinquish", target: "23: technologies", fill: "#fff700"},
{source: "23: technologies", target: "23: candidates", fill: "#fff700"},
{source: "23: additional", target: "78: generation", fill: "#645452"},
{source: "78: generation", target: "78: technology", fill: "#645452"},
{source: "78: technology", target: "78: development", fill: "#645452"},
{source: "78: development", target: "78: yet entered human clinical trials", fill: "#645452"},
{source: "78: generation", target: "START_HERE", fill: "#645452"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bavarian_Nordic">Bavarian Nordic</a></td>
      <td>Bavarian Nordic A/S is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company is headquartered in Hellerup, Denmark, with a manufacturing facility in Kvistgård, and an additional site in Hørsholm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of whom 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SEATTLE GENETICS INC /WA      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>You <font color="blue">should carefully</font> consider the <font color="blue">risks described</font> below, <font color="blue">together with</font> all     of the other information included in this annual report on Form 10-K and the     information <font color="blue">incorporated by reference herein</font></td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">effectively</font>     address the risks we face, our business will suffer and we may never achieve     or <font color="blue">sustain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>See “Management’s Discussion and Analysis of     <font color="blue">Financial Condition and Results of Operations</font></td>
    </tr>
    <tr>
      <td>”         <font color="blue">This Annual Report </font>on Form 10-K also contains forward-looking statements     that  <font color="blue">involve risks</font> and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>Our actual results <font color="blue">could differ</font>     <font color="blue">materially from</font> those anticipated in the forward-looking statements as a     result of factors that are described below and elsewhere in this annual     report on Form 10-K         Our <font color="blue">product <font color="blue">candidates</font></font> are <font color="blue">at early stages</font> of <font color="blue">development</font> and, if we are not     able to <font color="blue">successfully</font> develop and <font color="blue"><font color="blue">commercialize</font> them</font>, we may not generate     <font color="blue">sufficient revenues</font> to continue our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>All  of  our  product  <font color="blue">candidates</font>  are in early stages of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant  </font><font color="blue">further research</font> and <font color="blue">development</font>, financial resources and     <font color="blue">personnel will</font> be required to develop <font color="blue"><font color="blue">commercially</font> viable products</font> and     obtain <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font></td>
    </tr>
    <tr>
      <td>Currently, SGN-30, SGN-40 and SGN-33 are in     clinical  trials  and  SGN-35,  SGN-70  and  SGN-75 are in preclinical     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We expect that much of our efforts and <font color="blue"><font color="blue">expenditures</font> over</font> the     <font color="blue">next few years will</font> be devoted to these clinical and <font color="blue">preclinical product</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have no products that have received <font color="blue"><font color="blue">regulatory</font> approval</font> for     <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>Our  ability  to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> depends on first     receiving FDA approval</td>
    </tr>
    <tr>
      <td>Thereafter, the commercial success of these product     <font color="blue">candidates</font> <font color="blue">will depend upon</font> their <font color="blue">acceptance</font> by physicians, patients, third     party payors and other key decision-makers as therapeutic and cost-effective     <font color="blue"><font color="blue">alternative</font>s</font> to <font color="blue">currently available products</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">gain approval</font>     from the FDA or to produce a <font color="blue"><font color="blue">commercially</font> successful product</font>, we may not be     able to earn <font color="blue">sufficient revenues</font> to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>We <font color="blue">will continue</font> to need <font color="blue"><font color="blue">significant</font> amounts</font> of <font color="blue"><font color="blue">additional</font> capital</font> that may     not be available to us</td>
    </tr>
    <tr>
      <td>We expect to make <font color="blue"><font color="blue">additional</font> capital</font> outlays and to increase operating     <font color="blue"><font color="blue">expenditures</font> over</font> the <font color="blue">next several years as</font> we <font color="blue">hire <font color="blue">additional</font> employees</font> and     support  our preclinical <font color="blue">development</font>, <font color="blue">manufacturing</font> and <font color="blue">clinical trial</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We will need to <font color="blue">seek <font color="blue">additional</font> funding through public</font> or     <font color="blue">private financings</font>, including <font color="blue">equity financings</font>, and through other means,     <font color="blue">such as <font color="blue"><font color="blue">collaboration</font>s</font></font> and <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font></td>
    </tr>
    <tr>
      <td>However, changes in our                                           17     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>business may occur that <font color="blue">would consume available capital resources sooner</font>     than  we expect</td>
    </tr>
    <tr>
      <td>If <font color="blue">adequate funds</font> are not available to us, we will be     required to delay, reduce the scope of or <font color="blue">eliminate one</font> or more of our     <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We do not know <font color="blue">whether <font color="blue">additional</font> financing will</font> be     available when needed, or that, if available, we will obtain <font color="blue">financing on</font>     terms favorable to our <font color="blue">stockholders</font> or us</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future capital <font color="blue"><font color="blue">requirement</font>s</font></font>     <font color="blue">will depend upon</font> a number of factors, including:           •   the size, <font color="blue">complexity</font> and timing of our clinical programs;           •   our receipt of milestone-based payments or other <font color="blue">revenue from</font> our     <font color="blue"><font color="blue">collaboration</font>s</font> or <font color="blue">license <font color="blue">arrangements</font></font>;           •   the ability to <font color="blue"><font color="blue">manufacture</font> sufficient drug supply</font> to complete clinical     trials;           •   progress with <font color="blue">clinical trial</font>s;           •   the time and costs involved in obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>;           •   the <font color="blue">costs associated with <font color="blue">acquisition</font>s</font> or licenses of <font color="blue">additional</font>     products, including licenses we may need to <font color="blue">commercialize</font> our products;           •   the costs involved in preparing, filing, prosecuting, maintaining and     <font color="blue">enforcing patent</font> claims;           •   the timing and cost of <font color="blue">milestone payment <font color="blue">obligations</font> as</font> our product     <font color="blue">candidates</font> progress <font color="blue">towards <font color="blue">commercialization</font></font>;           •   <font color="blue">competing technological</font> and market <font color="blue">development</font>s; and           •   <font color="blue">preparation</font> for <font color="blue">product <font color="blue">commercialization</font></font></td>
    </tr>
    <tr>
      <td>To the extent that we raise <font color="blue"><font color="blue">additional</font> capital</font> by issuing <font color="blue">equity securities</font>,     our <font color="blue">stockholders</font> may experience substantial dilution</td>
    </tr>
    <tr>
      <td>To the extent that we     raise <font color="blue">additional</font> funds through <font color="blue">collaboration</font> and licensing <font color="blue">arrangements</font>, we     may be required to <font color="blue">relinquish</font> some rights to our <font color="blue">technologies</font> or product     <font color="blue">candidates</font>, or grant licenses on terms that are not favorable to us</td>
    </tr>
    <tr>
      <td>Clinical trials for our <font color="blue">product <font color="blue">candidates</font></font> are expensive, time consuming and     their outcome is uncertain</td>
    </tr>
    <tr>
      <td>Before we can obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for the <font color="blue">commercial sale</font> of any     <font color="blue">product candidate</font> that we wish to develop, we are required to complete     preclinical  <font color="blue">development</font>  and  extensive  <font color="blue">clinical trial</font>s in humans to     <font color="blue">demonstrate</font> its safety and efficacy</td>
    </tr>
    <tr>
      <td>Each of these trials requires the     <font color="blue">investment</font> of substantial expense and time</td>
    </tr>
    <tr>
      <td>We are <font color="blue">currently conducting</font>     phase II <font color="blue">clinical trial</font>s of our most advanced <font color="blue">product candidate</font> and phase I     <font color="blue">clinical trial</font>s of two <font color="blue">additional</font> <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We expect to commence     <font color="blue">additional</font> trials of these and other <font color="blue">product <font color="blue">candidates</font></font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">There     </font>are <font color="blue">numerous factors</font> that <font color="blue">could delay each</font> of these <font color="blue">clinical trial</font>s or     <font color="blue">prevent us from</font> completing these trials <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td><font color="blue">Commercialization </font>of our <font color="blue">product <font color="blue">candidates</font></font> will ultimately depend upon     successful <font color="blue">completion</font> of <font color="blue">additional</font> research and <font color="blue">development</font> and testing in     both <font color="blue">clinical trial</font>s and preclinical models</td>
    </tr>
    <tr>
      <td>At the present time, SGN-30,     SGN-40 and SGN-33 are our only <font color="blue">product <font color="blue">candidates</font></font> in clinical <font color="blue">development</font>     and SGN-35, SGN-70 and SGN-75 are our only <font color="blue">product <font color="blue">candidates</font></font> in preclinical     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>As a result, any delays or <font color="blue"><font color="blue">difficult</font>ies</font> we encounter with these     <font color="blue">product <font color="blue">candidates</font></font> may impact our ability to <font color="blue">generate revenue</font> and cause our     stock price to decline <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>Ongoing and future <font color="blue">clinical trial</font>s of our <font color="blue">product <font color="blue">candidates</font></font> may not show     sufficient safety or efficacy to obtain requisite <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">still only</font> have limited <font color="blue">efficacy data from</font> our phase I and phase II clinical     trials of SGN-30 and our phase I <font color="blue">clinical trial</font>s of SGN-40, and we only     recently commenced our phase I <font color="blue">clinical trial</font> of SGN-33</td>
    </tr>
    <tr>
      <td>Phase I and phase     II <font color="blue">clinical trial</font>s are not <font color="blue">primarily designed</font> to test the efficacy of a drug     candidate  but  rather  to  <font color="blue">test safety</font>, to <font color="blue">study <font color="blue">pharmacokinetics</font></font> and     <font color="blue">pharmacodynamics</font> and to understand the <font color="blue">drug candidate</font>’s side <font color="blue">effects at</font>     <font color="blue">various doses</font> and <font color="blue">dosing schedules</font></td>
    </tr>
    <tr>
      <td>Furthermore, success in preclinical and     early                                           18     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>clinical  trials does not ensure that later large-scale trials will be     <font color="blue">successful nor</font> does it <font color="blue">predict final</font> results</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptable </font>results in early     <font color="blue">trials may</font> not be repeated in <font color="blue">later trials</font></td>
    </tr>
    <tr>
      <td>We believe that any clinical     <font color="blue">trial designed</font> to test the efficacy of SGN-30, SGN-40 or SGN-33, whether     phase II or phase III, will likely involve a large number of patients to     achieve <font color="blue">statistical significance</font> and will be expensive</td>
    </tr>
    <tr>
      <td>We may conduct     lengthy and expensive <font color="blue">clinical trial</font>s of SGN-30, SGN-40 or SGN-33, only to     learn  that  the  <font color="blue">drug candidate</font> is not an <font color="blue">effective treatment</font></td>
    </tr>
    <tr>
      <td>We may     experience <font color="blue"><font color="blue">significant</font> setbacks</font> in advanced <font color="blue">clinical trial</font>s, even after     promising results in <font color="blue">earlier trials</font></td>
    </tr>
    <tr>
      <td>In addition, clinical results are     <font color="blue">frequently susceptible</font> to <font color="blue">varying <font color="blue">interpretations</font></font> that may delay, limit or     prevent <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font></td>
    </tr>
    <tr>
      <td>Negative or <font color="blue">inconclusive</font> results or adverse     medical  events during a <font color="blue">clinical trial</font> could cause it to be redone or     terminated</td>
    </tr>
    <tr>
      <td>For example, although we <font color="blue">generated data showing</font> an <font color="blue">encouraging</font>     trend in our phase II <font color="blue">clinical trial</font>s of SGN-15, we decided to <font color="blue">discontinue</font>     <font color="blue">development</font> of SGN-15 to prioritize our other programs</td>
    </tr>
    <tr>
      <td>In addition, failure     to construct <font color="blue">appropriate</font> <font color="blue">clinical trial</font> protocols could result in the test     or control group experiencing a <font color="blue">disproportionate</font> number of <font color="blue">adverse events</font>     and could cause a <font color="blue">clinical trial</font> to be redone or terminated</td>
    </tr>
    <tr>
      <td>The length of     time <font color="blue">necessary</font> to complete <font color="blue">clinical trial</font>s and to submit an <font color="blue">application</font> for     <font color="blue">marketing approval</font> for a <font color="blue">final <font color="blue">decision by</font></font> the FDA or another <font color="blue">regulatory</font>     authority may also vary <font color="blue"><font color="blue">significant</font>ly</font> based on the type, <font color="blue">complexity</font> and     novelty of the product involved, as well as other factors</td>
    </tr>
    <tr>
      <td>Our <font color="blue">clinical trial</font>s may take longer to complete than we project or they may     not be completed at all</td>
    </tr>
    <tr>
      <td>The timing of the commencement, continuation and <font color="blue">completion</font> of clinical     <font color="blue">trials may</font> be subject to <font color="blue"><font color="blue">significant</font> delays</font> relating to various causes,     including <font color="blue">scheduling conflicts with participating clinicians</font> and clinical     <font color="blue">institutions</font>, <font color="blue"><font color="blue">difficult</font>ies</font> in identifying and <font color="blue">enrolling patients</font> who meet     <font color="blue">trial <font color="blue">eligibility</font> criteria</font>, and shortages of <font color="blue">available drug supply</font></td>
    </tr>
    <tr>
      <td><font color="blue">Patient     </font><font color="blue">enrollment</font> is a function of many factors, including the size of the patient     population, the proximity of patients to <font color="blue">clinical sites</font>, the <font color="blue">eligibility</font>     criteria for the trial, the existence of competing <font color="blue">clinical trial</font>s and the     <font color="blue">availability</font>  of  <font color="blue">alternative</font>  or  <font color="blue">new <font color="blue">treatments</font></font></td>
    </tr>
    <tr>
      <td>We have experienced     <font color="blue">enrollment</font>-related delays in our current and previous <font color="blue">clinical trial</font>s and     may experience similar delays in our <font color="blue">future trials</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on medical</font>     <font color="blue">institutions</font> and clinical research <font color="blue">organization</font>s to conduct our clinical     trials and to the extent they fail to <font color="blue">enroll patients</font> for our clinical     trials or are delayed for a <font color="blue">significant</font> time in achieving full <font color="blue">enrollment</font>,     we may be affected by <font color="blue">increased costs</font>, program delays or both, which may     harm our business</td>
    </tr>
    <tr>
      <td>In addition, we may conduct <font color="blue">clinical trial</font>s in foreign     countries in the <font color="blue">future which may</font> subject us to <font color="blue">further delays</font> and expenses     as  a  result  of increased drug shipment costs, <font color="blue">additional</font> <font color="blue">regulatory</font>     <font color="blue"><font color="blue">requirement</font>s</font> and the <font color="blue">engagement</font> of <font color="blue">foreign clinical research <font color="blue">organization</font>s</font>,     <font color="blue">as well as expose us</font> to <font color="blue">risks associated with <font color="blue">foreign currency</font> <font color="blue">transactions</font></font>     <font color="blue">insofar as</font> we might desire to use US dollars to make <font color="blue">contract payments</font>     <font color="blue">denominated</font> in the <font color="blue">foreign currency</font> where the trial is being conducted</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials must</font> be conducted in <font color="blue">accordance with</font> FDA or other applicable     foreign government guidelines and are subject to <font color="blue">oversight by</font> the FDA, other     foreign <font color="blue">governmental</font> agencies and <font color="blue">institutional</font> review boards at the medical     <font color="blue">institutions</font> where the <font color="blue">clinical trial</font>s are conducted</td>
    </tr>
    <tr>
      <td>In addition, clinical     <font color="blue">trials must</font> be <font color="blue">conducted with supplies</font> of our <font color="blue">product <font color="blue">candidates</font></font> produced     under the FDA’s current <font color="blue">Good Manufacturing Practices </font>and other <font color="blue"><font color="blue">requirement</font>s</font>     in <font color="blue">foreign countries</font>, and may require large numbers of <font color="blue">test patients</font></td>
    </tr>
    <tr>
      <td>We,     the FDA or other foreign <font color="blue">governmental</font> agencies could delay or halt our     <font color="blue">clinical trial</font>s of a <font color="blue">product candidate</font> for <font color="blue">various reasons</font>, including:           •   <font color="blue">deficiencies</font> in the conduct of the <font color="blue">clinical trial</font>s;           •   the <font color="blue">product candidate</font> may have <font color="blue">unforeseen adverse</font> side effects;           •   the time required to determine whether the <font color="blue">product candidate</font> is     <font color="blue">effective may</font> be <font color="blue">longer than</font> expected;           •   <font color="blue">fatalities</font> or other <font color="blue">adverse events</font> arising during a <font color="blue">clinical trial</font> due     to <font color="blue">medical problems</font> that may not be related to <font color="blue">clinical trial</font> <font color="blue">treatments</font>;           •   the <font color="blue">product candidate</font> may not appear to be more <font color="blue"><font color="blue">effective than</font> current</font>     therapies;                                           19     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>  •   quality or stability of the <font color="blue">product candidate</font> may fall below     acceptable standards; or           •   we may not be able to produce <font color="blue">sufficient quantities</font> of the product     candidate to complete the trials</td>
    </tr>
    <tr>
      <td>Due to these and other factors, our current <font color="blue">product <font color="blue">candidates</font></font> or any of our     other future <font color="blue">product <font color="blue">candidates</font></font> could take a <font color="blue"><font color="blue">significant</font>ly</font> longer time to     gain <font color="blue"><font color="blue">regulatory</font> approval</font> than we expect or may never <font color="blue">gain approval</font>, which     could  reduce  or eliminate our <font color="blue">revenue by delaying</font> or <font color="blue">terminating</font> the     <font color="blue">potential <font color="blue">commercialization</font></font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We currently rely on third-party <font color="blue"><font color="blue">manufacture</font>rs</font> and other <font color="blue">third parties</font> for     production of our <font color="blue">drug products</font> and our <font color="blue">dependence on</font> these <font color="blue"><font color="blue">manufacture</font>rs</font>     may impair the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We do not currently have the ability to <font color="blue"><font color="blue">manufacture</font> ourselves</font> the drug     products that we need to conduct our <font color="blue">clinical trial</font>s and rely upon a limited     number  of  <font color="blue"><font color="blue">manufacture</font>rs</font>  to supply our <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>For SGN-30, we     <font color="blue">contracted with</font> ICOS to <font color="blue">manufacture</font> preclinical and early-stage clinical     supplies and with <font color="blue">Abbott Laboratories </font>for later-stage clinical and potential     future commercial supplies</td>
    </tr>
    <tr>
      <td>For SGN-40, Genentech <font color="blue">manufacture</font>d initial     quantities of clinical grade material that have <font color="blue">been transferred</font> to us, and     we have <font color="blue">contracted with</font> <font color="blue">Abbott Laboratories </font>for later-stage clinical and     potential future commercial supplies</td>
    </tr>
    <tr>
      <td>For SGN-33, we received clinical-grade     material from <font color="blue">PDL BioPharma </font>to support currently planned phase I trials and     plan to enter into contract <font color="blue">manufacturing</font> <font color="blue">arrangements</font> to supplement these     supplies as <font color="blue">necessary</font></td>
    </tr>
    <tr>
      <td>For SGN-35, we are utilizing antibody <font color="blue">manufacture</font>d by     Abbott, have <font color="blue">contracted with</font> <font color="blue">Albany Molecular Research for GMP </font><font color="blue">manufacturing</font>     of  our <font color="blue">proprietary</font> drug-linker system and are working with a contract     <font color="blue">manufacturing</font>  <font color="blue">organization</font>  for  <font color="blue">conjugation</font>  of  the antibody to the     <font color="blue">proprietary</font>  drug-linker  system</td>
    </tr>
    <tr>
      <td>We  are  also  planning  a contract     <font color="blue">manufacturing</font> campaign during 2006 to support our planned <font color="blue">initiation</font> of     <font color="blue">clinical trial</font>s with SGN-70 in 2007</td>
    </tr>
    <tr>
      <td>In addition, we rely on other third     parties to perform <font color="blue">additional</font> steps in the <font color="blue">manufacturing</font> process, including     vialing and storage of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>For  the foreseeable future, we expect to continue to rely on contract     <font color="blue"><font color="blue">manufacture</font>rs</font> and other <font color="blue">third parties</font> to produce, vial and <font color="blue">store sufficient</font>     quantities of our <font color="blue">product <font color="blue">candidates</font></font> for use in our <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>If our     contract <font color="blue"><font color="blue">manufacture</font>rs</font> or other <font color="blue">third parties</font> fail to deliver our product     <font color="blue">candidates</font> for <font color="blue">clinical use on</font> a timely basis, with sufficient quality, and     at  <font color="blue">commercially</font>  reasonable  prices,  and we fail to <font color="blue">find <font color="blue">replacement</font></font>     <font color="blue"><font color="blue">manufacture</font>rs</font> or to develop our own <font color="blue">manufacturing</font> cap<font color="blue">abilities</font>, we may be     required  to delay or suspend <font color="blue">clinical trial</font>s or otherwise <font color="blue">discontinue</font>     <font color="blue">development</font> and production of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition, we depend     <font color="blue">on outside vendors</font> for the supply of <font color="blue">raw materials used</font> to produce our     <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">third party</font> suppliers were to cease production or     otherwise fail to supply us with quality raw materials and we were unable to     contract  on acceptable terms for these raw materials with <font color="blue">alternative</font>     suppliers, our ability to have our <font color="blue">product <font color="blue">candidates</font></font> <font color="blue">manufacture</font>d and to     <font color="blue">conduct preclinical testing</font> and <font color="blue">clinical trial</font>s of our <font color="blue">product <font color="blue">candidates</font></font>     would be <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>Securing phase III and commercial quantities of our <font color="blue">product <font color="blue">candidates</font></font> from     contract <font color="blue"><font color="blue">manufacture</font>rs</font> will require us to commit <font color="blue">significant</font> capital and     resources</td>
    </tr>
    <tr>
      <td>We may also be required to enter into long-term <font color="blue">manufacturing</font>     <font color="blue"><font color="blue">agreement</font>s</font>  that  contain  <font color="blue">exclusivity</font>  provisions  and/or substantial     <font color="blue"><font color="blue">termination</font> penalties</font></td>
    </tr>
    <tr>
      <td>In addition, contract <font color="blue"><font color="blue">manufacture</font>rs</font> have a limited     number of <font color="blue">facilities</font> in which our <font color="blue">product <font color="blue">candidates</font></font> can be produced and any     <font color="blue">interruption</font> of the operation of those <font color="blue">facilities</font> due to <font color="blue">events such as</font>     equipment  <font color="blue">malfunction</font> or failure or damage to the <font color="blue">facility by natural</font>     <font color="blue">disasters could</font> result in the <font color="blue">cancellation</font> of shipments, loss of product in     the <font color="blue">manufacturing</font> process or a shortfall in available <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our contract <font color="blue"><font color="blue">manufacture</font>rs</font> are required to produce our clinical product     <font color="blue">candidates</font> under FDA current <font color="blue">Good Manufacturing Practices </font>in order to meet     acceptable standards for our <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>If <font color="blue">such standards</font> change, the     ability of contract <font color="blue"><font color="blue">manufacture</font>rs</font> to produce our <font color="blue">product <font color="blue">candidates</font></font> on the     schedule we require for our <font color="blue">clinical trial</font>s may be affected</td>
    </tr>
    <tr>
      <td>In addition,     contract  <font color="blue"><font color="blue">manufacture</font>rs</font>  may not perform their <font color="blue"><font color="blue">obligations</font> under</font> their     <font color="blue"><font color="blue">agreement</font>s</font>  with  us or may <font color="blue">discontinue</font> their business before the time     required by us to <font color="blue">successfully</font> produce and market our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">difficult</font>ies</font> or delays in our contractors’ <font color="blue">manufacturing</font> and supply of     <font color="blue">product <font color="blue">candidates</font></font> could increase our costs, cause us to <font color="blue">lose revenue</font> or     make us postpone or cancel <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>The FDA requires that we <font color="blue">demonstrate</font> structural and <font color="blue">functional <font color="blue">comparability</font></font>     between the same drug product <font color="blue">manufacture</font>d by different <font color="blue">organization</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we have used or intend to <font color="blue">use multiple sources</font> to <font color="blue">manufacture</font>     SGN-30, SGN-40 and SGN-33, we will need to <font color="blue">conduct <font color="blue">comparability</font> studies</font> to     assess whether <font color="blue">manufacturing</font> changes have affected the <font color="blue">product safety</font>,     identity, purity or potency of any commercial <font color="blue">drug candidate</font> compared to the     <font color="blue">drug candidate</font> used in <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">demonstrate</font>     <font color="blue">comparability</font>, the FDA could require us to conduct <font color="blue">additional</font> clinical     trials,   which   would  be  expensive  and  <font color="blue"><font color="blue">significant</font>ly</font>  delay  any     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>Our  second  <font color="blue">generation</font>  ADC  <font color="blue">technology</font> is still at an early-stage of     <font color="blue">development</font> and has not yet entered human <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>Our second <font color="blue">generation</font> ADC <font color="blue">technology</font>, utilizing <font color="blue">proprietary</font> stable linkers     and highly potent cell-killing drugs, is still at a <font color="blue">relatively early stage</font>     of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>This ADC <font color="blue">technology</font> is used in our SGN-35 and SGN-75 product     <font color="blue">candidates</font>  and is the basis of our <font color="blue"><font color="blue">collaboration</font>s</font> with Genentech, UCB     Celltech, PDL BioPharma, CuraGen, Bayer, MedImmune and PSMA Development     Company</td>
    </tr>
    <tr>
      <td>We and our corporate <font color="blue">collaborators</font> are still conducting toxicology,     <font color="blue">pharmacology</font>,  <font color="blue">pharmacokinetics</font>  and  other  preclinical  studies, and     <font color="blue">significant</font> <font color="blue">additional</font> studies will be required before any of these ADC     product  <font color="blue">candidates</font>  enter human <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>For example, we have     observed  evidence of toxicity in some <font color="blue">preclinical models with certain</font>     drug-linker  forms and are focusing our <font color="blue">efforts on forms with</font> the best     efficacy and <font color="blue">lowest toxicity</font> in order to maximize the <font color="blue">therapeutic window</font> of     our ADC <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, preclinical models to study anti-cancer     activity of compounds are not <font color="blue">necessarily predictive</font> of toxicity or efficacy     of  these  compounds  in the treatment of <font color="blue">human cancer</font> and there is no     assurance that we will be able to use these <font color="blue">technologies</font> in the treatment of     humans</td>
    </tr>
    <tr>
      <td>Any failures or setbacks in our ADC <font color="blue">program could</font> have a <font color="blue">detrimental</font>     impact  on  our internal <font color="blue">product candidate</font> pipeline and our ability to     maintain and/or enter into new corporate <font color="blue"><font color="blue">collaboration</font>s</font> regarding these     <font color="blue">technologies</font>, which would negatively affect our business and financial     position</td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur net losses</font>     and may not achieve or maintain <font color="blue">profitability</font> for some time, if at all</td>
    </tr>
    <tr>
      <td>We have incurred substantial net losses in each of our years of operation     and, as of <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of <font color="blue">approximately</font>     dlra143dtta6  million</td>
    </tr>
    <tr>
      <td>We expect to make substantial <font color="blue">expenditures</font> to further     develop and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font> and anticipate that our     rate of <font color="blue">spending will <font color="blue">accelerate</font> as</font> the result of the <font color="blue">increased costs</font> and     expenses  associated  with  research,  <font color="blue">development</font>,  clinical  trials,     <font color="blue">manufacturing</font>, <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> and <font color="blue">commercialization</font> of our potential     products</td>
    </tr>
    <tr>
      <td>In the near term, we expect our revenues to be derived from     <font color="blue">technology</font> licensing fees, sponsored research fees and milestone payments     under existing and future <font color="blue">collaborative</font> <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>In the longer term,     our revenues may also include royalties from <font color="blue"><font color="blue">collaboration</font>s</font> with current and     future strategic partners and commercial product sales</td>
    </tr>
    <tr>
      <td>However, our revenue     and <font color="blue">profit potential</font> is unproven and our limited operating history makes our     future operating results <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>We have <font color="blue">never been profitable</font>     and may never achieve <font color="blue">profitability</font> and if we do achieve <font color="blue">profitability</font>, it     may not be sustainable</td>
    </tr>
    <tr>
      <td>In some <font color="blue">circumstances</font> we rely on <font color="blue">collaborators</font> to assist in the research and     <font color="blue">development</font> <font color="blue">activities</font> <font color="blue">necessary</font> for the <font color="blue">commercialization</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If we are not able to locate suitable <font color="blue">collaborators</font> or if our     <font color="blue">collaborators</font>  do  not  perform  as  expected,  we  may not be able to     <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have established and intend to continue to <font color="blue">establish alliances with</font>     third-party <font color="blue">collaborators</font> to develop and market some of our current and     future  product  <font color="blue">candidates</font> and to license our ADC <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We have     licensed our ADC <font color="blue">technology</font> to Genentech, UCB Celltech, PDL BioPharma,     CuraGen, Bayer, MedImmune and PSMA Development Company</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">collaboration</font>s</font>     <font color="blue">provide us with cash</font> and revenues through <font color="blue">technology</font> access and license     fees, sponsored research fees, equity sales and <font color="blue">potential milestone</font> and     <font color="blue">royalty payments</font></td>
    </tr>
    <tr>
      <td>We use these funds to <font color="blue">partially fund</font> the <font color="blue">development</font> costs     of our <font color="blue">internal pipeline</font> of <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Collaborations </font>can also     create and strengthen our <font color="blue"><font color="blue">relationships</font> with</font> leading bio<font color="blue">technology</font> and     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> and <font color="blue">may provide synergistic benefits by combining</font>     our <font color="blue">technologies</font> with the <font color="blue">technologies</font> of our                                           21     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font><font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>For example, in July 2004, we formed a <font color="blue">collaboration</font> with     <font color="blue">Celera Genomics </font>to jointly discover and develop antibody-based therapies for     cancer</td>
    </tr>
    <tr>
      <td>Under <font color="blue">certain conditions</font>, our <font color="blue">collaborators</font> may terminate their <font color="blue"><font color="blue">agreement</font>s</font>     with us and <font color="blue">discontinue</font> use of our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control</font> the     amount and timing of resources our <font color="blue">collaborators</font> may devote to products     <font color="blue">incorporating</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue"><font color="blue">relationships</font> with</font> our     <font color="blue">collaborators</font> divert <font color="blue">significant</font> time and effort of our <font color="blue">scientific staff</font> and     <font color="blue">management</font>  team  and require <font color="blue">effective allocation</font> of our resources to     multiple  internal  and  <font color="blue">collaborative</font> projects</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> may     separately pursue competing products, therapeutic approaches or <font color="blue">technologies</font>     to develop <font color="blue">treatments</font> for the <font color="blue">diseases targeted by us</font> or our <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>Even if our <font color="blue">collaborators</font> continue their <font color="blue">contributions</font> to the <font color="blue">collaborative</font>     <font color="blue">arrangements</font>, they <font color="blue">may nevertheless</font> determine not to <font color="blue">actively pursue</font> the     <font color="blue">development</font>  or  <font color="blue">commercialization</font>  of  any  resulting  products</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborators</font> may fail to perform their <font color="blue"><font color="blue">obligations</font> under</font> the <font color="blue">collaboration</font>     <font color="blue"><font color="blue">agreement</font>s</font> or may be slow in performing their <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>If any of our     <font color="blue">collaborators</font> terminate or breach our <font color="blue"><font color="blue">agreement</font>s</font> with them, or otherwise     fail  to  complete their <font color="blue">obligations</font> in a <font color="blue">timely manner</font>, it may have a     <font color="blue">detrimental</font> effect on our <font color="blue"><font color="blue">financial position</font> by reducing</font> or <font color="blue">eliminating</font> the     potential for us to receive <font color="blue">technology</font> access and license fees, <font color="blue">milestones</font>     and royalties, as well as possibly requiring us to devote <font color="blue">additional</font> efforts     and incur costs associated with pursuing internal <font color="blue">development</font> of product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Furthermore, if our <font color="blue">collaborators</font> do not prioritize and commit     substantial resources to <font color="blue">programs associated with</font> our <font color="blue">product <font color="blue">candidates</font></font>, we     may be unable to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>, which would limit our     ability to <font color="blue">generate revenue</font> and <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>In the future, we may not     be  able to locate <font color="blue">third party</font> <font color="blue">collaborators</font> to develop and market our     <font color="blue">product <font color="blue">candidates</font></font> and we may lack the capital and resources <font color="blue">necessary</font> to     develop all our <font color="blue">product <font color="blue">candidates</font></font> alone</td>
    </tr>
    <tr>
      <td>We  depend  on a small number of <font color="blue">collaborators</font> for most of our current     revenue</td>
    </tr>
    <tr>
      <td>The loss of any one of these <font color="blue">collaborators</font> could result in a     substantial decline in our revenue</td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">collaboration</font>s</font> with a limited number of companies</td>
    </tr>
    <tr>
      <td>To date, almost     all of our revenue has resulted <font color="blue">from payments</font> made under <font color="blue"><font color="blue">agreement</font>s</font> with our     corporate <font color="blue">collaborators</font>, and we expect that most of our <font color="blue">future revenue will</font>     continue  to come from corporate <font color="blue"><font color="blue">collaboration</font>s</font> until the approval and     <font color="blue">commercialization</font> of one or more of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>The failure of     our <font color="blue">collaborators</font> to perform their <font color="blue"><font color="blue">obligations</font> under</font> their <font color="blue"><font color="blue">agreement</font>s</font> with     us, including <font color="blue">paying license</font> or <font color="blue">technology</font> fees, milestone payments or     royalties,  could  have  a  material  adverse  effect on our financial     performance</td>
    </tr>
    <tr>
      <td>In addition, a <font color="blue">significant</font> portion of revenue received from our     corporate <font color="blue">collaborators</font> is <font color="blue">derived from research</font> and material supply fees,     and  a  <font color="blue">decision by</font> any of our corporate <font color="blue">collaborators</font> to conduct more     research and <font color="blue">development</font> <font color="blue">activities</font> themselves could <font color="blue"><font color="blue">significant</font>ly</font> reduce     the revenue received from these <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>Payments under our existing     and  future  <font color="blue">collaboration</font>  <font color="blue"><font color="blue">agreement</font>s</font> are also subject to <font color="blue">significant</font>     <font color="blue">fluctuations</font> in <font color="blue">both timing</font> and amount, <font color="blue">which could</font> cause our revenue to     fall below the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> and investors and cause a     decrease in our stock price</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> for <font color="blue">certain aspects</font> of our <font color="blue">product <font color="blue">candidates</font></font>     and <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Failure to maintain these <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> or to secure     any  required  new  licenses  could  prevent  us  from  developing  or     <font color="blue">commercializing</font> our <font color="blue">product <font color="blue">candidates</font></font> and <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We have entered into <font color="blue"><font color="blue">agreement</font>s</font> with third-party commercial and academic     <font color="blue">institutions</font> to license <font color="blue">technology</font> for use in our ADC <font color="blue">technology</font> and product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Currently, we have <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> with Bristol-Myers Squibb,     Arizona  State  University, Genentech, PDL BioPharma, CLB Research and     Development, ICOS Corporation, Mabtech AB, and the University of Miami,     among  others</td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> contain diligence and     milestone-based <font color="blue">termination</font> provisions, in which case our failure to meet     any agreed upon diligence <font color="blue"><font color="blue">requirement</font>s</font> or <font color="blue">milestones</font> may allow the licensor     to  terminate  the  <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> grant us     exclusive  licenses  to  the underlying <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">licensors</font>     terminate  our  <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font> or if we are unable to maintain the     <font color="blue">exclusivity</font>  of  our exclusive <font color="blue">license <font color="blue"><font color="blue">agreement</font>s</font></font>, we may be unable to     continue to develop and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In addition,     continued <font color="blue">development</font> and <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font> may     require us to <font color="blue">secure licenses</font> to <font color="blue">additional</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We may not be able     to secure these licenses on <font color="blue">commercially</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>We  rely  on  <font color="blue">third parties</font> to <font color="blue">provide services</font> in <font color="blue">connection with</font> our     preclinical and clinical <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>The inadequate <font color="blue">performance by</font>     or loss of any of these <font color="blue"><font color="blue">service providers</font> could affect</font> our <font color="blue">product candidate</font>     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Several <font color="blue">third parties</font> <font color="blue">provide services</font> in <font color="blue">connection with</font> our preclinical     and clinical <font color="blue">development</font> programs, including in vitro and in <font color="blue">vivo studies</font>,     assay   and  reagent  <font color="blue">development</font>,  <font color="blue">immunohistochemistry</font>,  toxicology,     <font color="blue">pharmacokinetics</font> and other outsourced <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">service providers</font>     do not <font color="blue">adequately</font> perform the services for which we have contracted or cease     to continue <font color="blue">operations</font> and we are not able to <font color="blue">quickly find</font> a <font color="blue">replacement</font>     provider  or  we lose information or <font color="blue">items associated with</font> our product     <font color="blue">candidates</font>, our <font color="blue">development</font> programs may be delayed</td>
    </tr>
    <tr>
      <td>If we are unable to enforce our <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font>, we may not be     able to <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Similarly, if we fail to     sustain and <font color="blue">further build</font> our <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font>, <font color="blue">competitors</font> may     be able to develop <font color="blue">competing therapies</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font>, in part, on obtaining and maintaining <font color="blue">patent protection</font>     and <font color="blue">successfully</font> defending these <font color="blue">patents against <font color="blue">third party</font> challenges</font> in     the <font color="blue"><font color="blue">United States</font> </font>and other countries</td>
    </tr>
    <tr>
      <td>We own multiple US and foreign     patents and pending patent <font color="blue">application</font>s for our <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We also have     rights  to issued US patents, patent <font color="blue">application</font>s, and their foreign     <font color="blue">counterparts</font>,  relating  to  our  monoclonal  antibody  and drug-based     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Our rights to these patents and patent <font color="blue">application</font>s are     derived in part <font color="blue">from worldwide licenses from</font> Bristol-Myers Squibb, Arizona     State University, Genentech and PDL BioPharma, <font color="blue">among others</font></td>
    </tr>
    <tr>
      <td>In addition, we     have licensed our US and foreign patents and patent <font color="blue">application</font>s to third     parties</td>
    </tr>
    <tr>
      <td>The standards that the <font color="blue">US Patent and Trademark Office </font>and foreign patent     offices use to grant patents are not always applied <font color="blue">predictably</font> or uniformly     and can change</td>
    </tr>
    <tr>
      <td>Consequently, our pending patent <font color="blue">application</font>s may not be     allowed and, if allowed, may not contain the type and extent of patent     claims  that  will  be  adequate  to  conduct our business as planned</td>
    </tr>
    <tr>
      <td>Additionally, any issued patents may not contain claims that will permit us     to stop <font color="blue">competitors</font> from using similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Similarly, the standards     that courts use to interpret patents are not always applied <font color="blue">predictably</font> or     uniformly and may evolve, <font color="blue">particularly</font> as new <font color="blue">technologies</font> develop</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on <font color="blue">trade secrets</font></font> and other <font color="blue">proprietary</font> information where we believe     <font color="blue">patent protection</font> is not <font color="blue">appropriate</font> or obtainable</td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font>     and other <font color="blue">proprietary</font> information are <font color="blue">difficult</font> to protect</td>
    </tr>
    <tr>
      <td>We have taken     measures to protect our unpatented <font color="blue">trade secrets</font> and know-how, including the     use of <font color="blue"><font color="blue">confidential</font>ity</font> and <font color="blue">assignment</font> of inventions <font color="blue"><font color="blue">agreement</font>s</font> with our     employees, consultants and <font color="blue">certain contractors</font></td>
    </tr>
    <tr>
      <td>It is possible, however,     that these <font color="blue">persons may breach</font> the <font color="blue"><font color="blue">agreement</font>s</font> or that our <font color="blue">competitors</font> may     <font color="blue">independently</font> develop or otherwise discover our <font color="blue">trade secrets</font> or other     <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>Our research <font color="blue">collaborators</font> may publish data and information to which we have     rights</td>
    </tr>
    <tr>
      <td>If we cannot maintain the <font color="blue"><font color="blue">confidential</font>ity</font> of our <font color="blue">technology</font> and     other <font color="blue">confidential</font> information in <font color="blue">connection with</font> our <font color="blue"><font color="blue">collaboration</font>s</font>, then     our  ability  to  receive <font color="blue">patent protection</font> or protect our <font color="blue">proprietary</font>     information may be impaired</td>
    </tr>
    <tr>
      <td>We may incur substantial costs and <font color="blue">lose important rights as</font> a result of     <font color="blue">litigation</font> or other <font color="blue">proceedings</font> relating to patent and other <font color="blue">intellectual</font>     <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td>The defense and <font color="blue">enforcement</font> of <font color="blue"><font color="blue">intellectual</font> <font color="blue">property rights</font></font> in a court of     law, <font color="blue">US Patent and Trademark Office </font>interference <font color="blue">proceedings</font> and related     legal and <font color="blue">administrative</font> <font color="blue">proceedings</font> in the <font color="blue"><font color="blue">United States</font> </font>and elsewhere     involve complex legal and factual questions</td>
    </tr>
    <tr>
      <td>These <font color="blue">proceedings</font> are costly     and time-consuming</td>
    </tr>
    <tr>
      <td>If we <font color="blue">become involved</font> in any <font color="blue">litigation</font>, interference or     other <font color="blue">administrative</font> <font color="blue">proceedings</font>, we will incur substantial expense and it     will  divert the efforts of our technical and <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>An     adverse de<font color="blue">termination</font> may subject us to <font color="blue">significant</font> li<font color="blue">abilities</font> or require     us  to  seek  licenses that may not be available from <font color="blue">third parties</font> on     <font color="blue">commercially</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>We may be restricted or prevented     from developing and <font color="blue">commercializing</font> our <font color="blue">product <font color="blue">candidates</font></font> in the event of     an adverse de<font color="blue">termination</font> in a judicial or <font color="blue"><font color="blue">administrative</font> proceeding</font>, or if     we fail to obtain <font color="blue">necessary</font> licenses</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>If we lose our <font color="blue">key personnel</font> or are unable to attract and retain <font color="blue">additional</font>     <font color="blue">qualified personnel</font>, our <font color="blue">future growth</font> and ability to <font color="blue">compete would suffer</font></td>
    </tr>
    <tr>
      <td>We  are <font color="blue">highly dependent on</font> the efforts and <font color="blue">abilities</font> of the principal     members of our senior <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Additionally, we have <font color="blue">several scientific</font>     personnel with <font color="blue">significant</font> and <font color="blue">unique expertise</font> in <font color="blue">monoclonal antibodies</font> and     related <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The loss of the services of any one of the principal     members of our managerial or <font color="blue">scientific staff</font> may <font color="blue">prevent us from</font> achieving     our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">competition</font> for <font color="blue">qualified personnel</font> in the bio<font color="blue">technology</font> field is     intense, and our future <font color="blue">success depends</font> upon our ability to attract, retain     and motivate highly skilled scientific, technical and <font color="blue">managerial employees</font></td>
    </tr>
    <tr>
      <td>In order to <font color="blue">commercialize</font> our products <font color="blue">successfully</font>, we will be required to     expand our workforce, <font color="blue">particularly</font> in the areas of <font color="blue">manufacturing</font>, clinical     trials <font color="blue">management</font>, <font color="blue">regulatory</font> affairs, business <font color="blue">development</font> and sales and     marketing</td>
    </tr>
    <tr>
      <td>These <font color="blue">activities</font> will require the addition of <font color="blue">new personnel</font>,     including  <font color="blue">management</font>,  and the <font color="blue">development</font> of <font color="blue">additional</font> expertise by     existing <font color="blue">management</font> personnel</td>
    </tr>
    <tr>
      <td>We face intense <font color="blue">competition</font> for qualified     <font color="blue"><font color="blue">individuals</font> from numerous <font color="blue">pharmaceutical</font></font> and bio<font color="blue">technology</font> companies, as     <font color="blue">well as academic</font> and other research <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td>To the extent we are not     able  to  attract and retain these <font color="blue">individuals</font> on favorable terms, our     business may be harmed</td>
    </tr>
    <tr>
      <td>We face intense <font color="blue">competition</font> and <font color="blue">rapid technological</font> change, which may result     in <font color="blue">others discovering</font>, developing or <font color="blue">commercializing</font> competing products     before or more <font color="blue">successfully</font> than we do</td>
    </tr>
    <tr>
      <td>The bio<font color="blue">technology</font> and <font color="blue"><font color="blue">pharmaceutical</font> industries</font> are <font color="blue">highly competitive</font> and     subject to <font color="blue">significant</font> and <font color="blue">rapid technological</font> change</td>
    </tr>
    <tr>
      <td>We are aware of many     <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies that are actively engaged in     research and <font color="blue">development</font> in areas related to <font color="blue">antibody therapy</font></td>
    </tr>
    <tr>
      <td>Some of these     <font color="blue">competitors</font>  have <font color="blue">successfully</font> <font color="blue">commercialize</font>d antibody products or are     developing  or testing <font color="blue">product <font color="blue">candidates</font></font> that do or may in the future     <font color="blue">compete directly with</font> our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>For example, we believe that     companies including Genentech, Amgen, ImmunoGen, Biogen IDEC, Medarex,     Chiron and Wyeth are developing and/or marketing products or <font color="blue">technologies</font>     that <font color="blue"><font color="blue">may compete with</font> ours</font></td>
    </tr>
    <tr>
      <td>Other potential <font color="blue">competitors</font> include large, fully     integrated <font color="blue"><font color="blue">pharmaceutical</font> companies</font> and more established bio<font color="blue">technology</font>     companies, which have <font color="blue">significant</font> resources and expertise in research and     <font color="blue">development</font>, <font color="blue">manufacturing</font>, testing, obtaining <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font> and     marketing</td>
    </tr>
    <tr>
      <td>Also, academic <font color="blue">institutions</font>, government agencies and other public     and private research <font color="blue">organization</font>s conduct research, seek <font color="blue">patent protection</font>     and  establish  <font color="blue">collaborative</font>  <font color="blue">arrangements</font> for research, <font color="blue">development</font>,     <font color="blue">manufacturing</font> and marketing</td>
    </tr>
    <tr>
      <td>It is possible that these <font color="blue">competitors</font> will     succeed in developing <font color="blue">technologies</font> that are more <font color="blue">effective than</font> our product     <font color="blue">candidates</font> or that would render our <font color="blue">technology</font> obsolete or <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> develop superior products, <font color="blue">manufacturing</font> capability or     <font color="blue">marketing expertise</font>, our business may fail</td>
    </tr>
    <tr>
      <td>Our  business  may fail because we face intense <font color="blue">competition</font> from major     <font color="blue"><font color="blue">pharmaceutical</font> companies</font> and specialized bio<font color="blue">technology</font> companies engaged in     the  <font color="blue">development</font>  of  other  products  <font color="blue">directed at cancer</font></td>
    </tr>
    <tr>
      <td>Many of our     <font color="blue">competitors</font> have greater financial and human resources expertise and more     experience in the <font color="blue">commercialization</font> of <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font>     may, among other things:           •   develop safer or more <font color="blue">effective products</font>;           •   implement more <font color="blue">effective approaches</font> to sales and marketing;           •   develop <font color="blue">less costly products</font>;           •   obtain quicker <font color="blue"><font color="blue">regulatory</font> approval</font>;           •   have access to more <font color="blue">manufacturing</font> <font color="blue">capacity</font>;           •   form more <font color="blue">advantageous strategic alliances</font>; or           •   establish superior <font color="blue">proprietary</font> positions</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>In  addition,  if we receive <font color="blue"><font color="blue"><font color="blue">regulatory</font> approval</font>s</font>, we <font color="blue">may compete with</font>     well-established, FDA-approved therapies that have generated substantial     <font color="blue">sales over</font> a number of years</td>
    </tr>
    <tr>
      <td>We anticipate that we <font color="blue">will face increased</font>     <font color="blue">competition</font> in the <font color="blue">future as new companies enter</font> our market and scientific     <font color="blue">development</font>s surrounding other <font color="blue">cancer therapies continue</font> to <font color="blue">accelerate</font></td>
    </tr>
    <tr>
      <td>We have no experience in <font color="blue">commercializing</font> products on our own and, to the     extent we do not develop this ability or <font color="blue">contract with</font> a <font color="blue">third party</font> to     <font color="blue">assist us</font>, we may not be able to <font color="blue">successfully</font> sell our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We do not have a sales and <font color="blue">marketing force</font> and may not be able to develop     this  <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>If  we  are  unable  to <font color="blue">establish sales</font> and marketing     cap<font color="blue">abilities</font>, we will need to <font color="blue">enter into sales</font> and marketing <font color="blue"><font color="blue">agreement</font>s</font> to     market our products in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">sales outside</font> the United     States, we plan to enter into third-party <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>In these foreign     markets, if we are unable to <font color="blue">establish successful <font color="blue">distribution</font> <font color="blue">relationships</font></font>     with  <font color="blue">pharmaceutical</font>  companies, we may fail to realize the full sales     potential of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Additionally, our <font color="blue">product <font color="blue">candidates</font></font> may not gain market <font color="blue">acceptance</font> among     physicians, patients, healthcare payors and the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>The     degree of market <font color="blue">acceptance</font> of any approved <font color="blue">product candidate</font> will depend on     a number of factors, including: <font color="blue">establishment</font> and <font color="blue">demonstration</font> of clinical     efficacy  and  safety;  cost-effectiveness of a product; its potential     advantage over <font color="blue">alternative</font> treatment methods; and marketing and <font color="blue">distribution</font>     support for the product</td>
    </tr>
    <tr>
      <td>Moreover, government health <font color="blue">administrative</font> authorities, private health     insurers and other <font color="blue">organization</font>s are <font color="blue">increasingly challenging both</font> the need     for  and the price of <font color="blue">new medical products</font> and services</td>
    </tr>
    <tr>
      <td>Consequently,     <font color="blue">uncertainty</font>  exists  as  to the <font color="blue"><font color="blue">reimbursement</font> status</font> of <font color="blue">newly approved</font>     <font color="blue">therapeutics</font> and <font color="blue">diagnostics</font></td>
    </tr>
    <tr>
      <td>For these and other reasons, physicians,     patients, third-party payors and the <font color="blue">medical community</font> may not accept and     utilize  any  product  <font color="blue">candidates</font> that we develop and even if they do,     <font color="blue"><font color="blue">reimbursement</font> may</font> not be available for our products to <font color="blue">enable us</font> to maintain     <font color="blue">price levels sufficient</font> to realize an <font color="blue">appropriate</font> return on our <font color="blue">investment</font>     in  research and product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Similarly, even if we do receive     <font color="blue">reimbursement</font>, the <font color="blue">target market</font> for our <font color="blue">products may</font> be small or the focus     of intense <font color="blue">competition</font> and we may not realize an <font color="blue">appropriate</font> return on our     <font color="blue">investment</font> in research and product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>The holders of our <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> have voting and     other rights that they <font color="blue">could exercise against</font> the <font color="blue">best interests</font> of our     common <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The holders of our <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> currently have     rights to <font color="blue">designate two members</font> of our <font color="blue">Board of <font color="blue">Directors </font></font>and to vote as a     separate class on certain <font color="blue">significant</font> corporate <font color="blue">transactions</font>, including the     issuance of securities that <font color="blue">would rank on</font> a par with or senior to the Series     A <font color="blue">convertible <font color="blue">preferred stock</font></font> or the incurrence of debt in excess of dlra20     million</td>
    </tr>
    <tr>
      <td>The  holders of <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> are not     entitled to receive any cumulative or non-cumulative dividends, and may only     receive a dividend when and as declared by our <font color="blue">Board of <font color="blue">Directors </font></font>or if any     dividends are paid on any other shares of our <font color="blue">capital stock based on</font> the     number of shares of <font color="blue">common stock</font> into which such holder’s shares of <font color="blue">Series A </font>    convertible  <font color="blue"><font color="blue">preferred stock</font> would then convert</font></td>
    </tr>
    <tr>
      <td>In addition, upon our     <font color="blue">liquidation</font> or <font color="blue">dissolution</font> (including a merger or <font color="blue">acquisition</font>), the holders     of  our <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> are entitled to receive a     <font color="blue">liquidation</font> preference in an amount equal to the greater of the original     <font color="blue">offering price</font> of dlra25dtta00 per share of <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font>     or the amount that would have been paid had each such share of <font color="blue">Series A </font>    <font color="blue">convertible <font color="blue">preferred stock</font></font> been converted to <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The holders of     <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> also have the right <font color="blue">under certain</font>     <font color="blue">circumstances</font> in the event of our merger or <font color="blue">acquisition</font> approved by our     <font color="blue">Board of <font color="blue">Directors </font></font>to receive their <font color="blue">liquidation</font> preference in cash or a     <font color="blue">combination</font>  of  cash and <font color="blue">new preferred securities</font> of the acquiring or     <font color="blue">surviving corporation</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">requirement</font> to pay cash or <font color="blue">issue new preferred</font>     securities does not apply if the <font color="blue">consideration</font> to be received by the Series     A holders has an <font color="blue">aggregate value</font> of more than dlra6dtta25 per share (<font color="blue">calculated on</font>     an as-if-converted to <font color="blue">common stock</font> basis) determined on the <font color="blue">date definitive</font>     <font color="blue">documentation</font> for <font color="blue">such sale transaction</font> is signed or if holders of 2/3rds of     the <font color="blue">outstanding shares</font> of <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> waive this     <font color="blue">requirement</font></td>
    </tr>
    <tr>
      <td>The  holders of <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> may     exercise these rights to the detriment of our common <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>The holders of our <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> also have the right     at any time to request that we register for resale the shares of our common     stock  that they acquire <font color="blue">upon conversion</font> of their <font color="blue">Series A </font>convertible     <font color="blue">preferred stock</font> or <font color="blue">upon exercise</font> of their warrants to purchase our common     stock, subject to <font color="blue">certain limitations</font></td>
    </tr>
    <tr>
      <td>In addition, the holders of our     <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font> may convert their <font color="blue">Series A </font>convertible     <font color="blue">preferred stock</font> into <font color="blue">common stock</font> at any time and <font color="blue">sell shares</font> of the common     stock acquired <font color="blue">upon such conversion</font> in the <font color="blue">public market</font> in <font color="blue">reliance upon</font>     Rule 144</td>
    </tr>
    <tr>
      <td>Future sales in the <font color="blue">public market</font> of such <font color="blue">common stock</font>, or the     <font color="blue">perception</font>  that  such  sales  might occur, could adversely affect the     <font color="blue">prevailing <font color="blue">market price</font></font> of our <font color="blue">common stock</font> and could make it more <font color="blue">difficult</font>     for us to <font color="blue">raise funds through</font> a <font color="blue">public offering</font> or <font color="blue">private placement</font> of our     <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face product <font color="blue">liability</font> risks</font> and may not be able to obtain adequate     insurance to <font color="blue">protect us against losses</font></td>
    </tr>
    <tr>
      <td>We currently have no products that have <font color="blue">been approved</font> for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>However, the current and future use of our <font color="blue">product <font color="blue">candidates</font></font> by us and our     corporate <font color="blue">collaborators</font> in <font color="blue">clinical trial</font>s, and the sale of any approved     products in the future, may expose us to <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>These claims     might be made <font color="blue">directly by consumers</font> or <font color="blue">healthcare providers</font> or <font color="blue">indirectly by</font>     <font color="blue"><font color="blue">pharmaceutical</font> companies</font>, our corporate <font color="blue">collaborators</font> or <font color="blue">others selling such</font>     products</td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">financial losses</font> in the future due to product     <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>We have obtained limited general commercial <font color="blue">liability</font>     insurance  coverage  for  our <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>We intend to expand our     <font color="blue">insurance coverage</font> to include the sale of <font color="blue">commercial products</font> if we obtain     <font color="blue">marketing approval</font> for any of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>However, we may not be     able to maintain <font color="blue">insurance coverage</font> at a <font color="blue">reasonable cost</font> or in sufficient     amounts to <font color="blue">protect us against losses</font></td>
    </tr>
    <tr>
      <td>If a successful product <font color="blue">liability</font>     claim or series of claims is brought against us for uninsured li<font color="blue">abilities</font> or     in excess of insured li<font color="blue">abilities</font>, our assets may not be sufficient to cover     such claims and our business <font color="blue">operations</font> could be impaired</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> involve <font color="blue">hazardous materials</font> and are subject to <font color="blue">environmental</font>,     health and <font color="blue">safety controls</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">environmental</font>, health and <font color="blue">safety laws</font> and <font color="blue">regulations</font>,     including  those governing the use of <font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>The cost of     compliance with <font color="blue">environmental</font>, health and safety <font color="blue">regulations</font> is substantial</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of <font color="blue">hazardous materials</font>     and we <font color="blue">cannot eliminate</font> the risk of <font color="blue"><font color="blue">accident</font>al contamination</font> or <font color="blue">injury from</font>     these materials</td>
    </tr>
    <tr>
      <td>In the event of an <font color="blue">accident</font> or <font color="blue">environmental</font> discharge, we     may be held liable for any resulting damages, which may materially harm our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may engage in future <font color="blue">acquisition</font>s that increase our capital <font color="blue"><font color="blue">requirement</font>s</font>,     dilute  our  <font color="blue">stockholders</font>, cause us to incur debt or assume <font color="blue">contingent</font>     li<font color="blue">abilities</font> and subject us to other risks</td>
    </tr>
    <tr>
      <td>We <font color="blue">actively evaluate various strategic <font color="blue">transactions</font> on</font> an <font color="blue">ongoing basis</font>,     including licensing or acquiring complementary products, <font color="blue">technologies</font> or     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Any potential <font color="blue">acquisition</font>s may entail numerous risks, including     increased  operating  expenses  and cash <font color="blue"><font color="blue">requirement</font>s</font>, assimilation of     <font color="blue">operations</font>  and products, retention of key employees, diversion of our     <font color="blue">management</font>’s attention and <font color="blue">uncertainties</font> in our ability to maintain key     business  <font color="blue">relationships</font>  of  the acquired entities</td>
    </tr>
    <tr>
      <td>In addition, if we     undertake <font color="blue">acquisition</font>s, we <font color="blue">may issue dilutive securities</font>, assume or incur     debt <font color="blue">obligations</font>, incur large one-time expenses and acquire intangible     assets  that  could result in <font color="blue">significant</font> future amortization expense</td>
    </tr>
    <tr>
      <td>Moreover, we may not be able to locate suitable <font color="blue">acquisition</font> opportunities     and this <font color="blue">inability could impair</font> our ability to grow or obtain access to     <font color="blue">technology</font> or products that may be important to the <font color="blue">development</font> of our     business</td>
    </tr>
    <tr>
      <td><font color="blue">Legislative </font>actions, potential new accounting <font color="blue">pronouncements</font> and higher     insurance  costs are likely to impact our <font color="blue">future <font color="blue">financial position</font></font> or     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Future  changes  in  <font color="blue">financial accounting standards may</font> cause adverse,     unexpected revenue <font color="blue">fluctuations</font> and affect our <font color="blue">financial position</font> or results     of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>New  <font color="blue">pronouncements</font>  and  varying  <font color="blue">interpretations</font> of     <font color="blue">pronouncements</font> have occurred <font color="blue">with frequency</font> in the past and may occur again     in the future and as a result we may be required to make changes in our     <font color="blue">accounting policies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with new <font color="blue">regulations</font> regarding corporate     governance and <font color="blue"><font color="blue">public disclosure</font> may</font> result in <font color="blue">additional</font> expenses</td>
    </tr>
    <tr>
      <td><font color="blue">Changing     </font>laws, <font color="blue">regulations</font> and                                           26     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>standards relating to <font color="blue">corporate governance</font> and <font color="blue">public disclosure</font>, including     the Sarbanes-Oxley Act of 2002, new SEC <font color="blue">regulations</font> and Nasdaq National     Market rules and the <font color="blue">recent accounting</font> changes to <font color="blue">expense stock options</font>, are     creating <font color="blue">uncertainty</font> for <font color="blue">companies such as ours</font> and <font color="blue">insurance costs</font> are     <font color="blue">increasing as</font> a result of this <font color="blue">uncertainty</font> and other factors</td>
    </tr>
    <tr>
      <td>As a result,     we  intend to invest all <font color="blue">reasonably</font> <font color="blue">necessary</font> resources to <font color="blue">comply with</font>     evolving standards, and this <font color="blue">investment</font> may result in increased general and     <font color="blue">administrative</font> expenses and a diversion of <font color="blue">management</font> time and attention     from science and business <font color="blue">activities</font> to compliance <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>For example,     we have incurred and expect to continue to incur substantial costs and     expend <font color="blue">significant</font> resources to <font color="blue">comply with</font> the <font color="blue">regulations</font> promulgated     under Section 404 of the Sarbanes-Oxley Act of 2002</td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price may</font> be volatile and our <font color="blue">shares may suffer</font> a decline in     value</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of bio<font color="blue">technology</font> companies have in the past     been, and are likely to continue in the future to be, very volatile</td>
    </tr>
    <tr>
      <td><font color="blue">During     </font>the fourth quarter of 2005, our stock price fluctuated between dlra4dtta50 and     dlra5dtta79 per share</td>
    </tr>
    <tr>
      <td>As a result of <font color="blue">fluctuations</font> in the price of our common     stock, you may be unable to sell your shares at or above the price you paid     for them</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> may be subject to substantial     <font color="blue">volatility</font> in response to many <font color="blue">risk factors listed</font> in this section, and     others beyond our control, including:           •   <font color="blue">announcements</font> regarding the results of <font color="blue">discovery efforts</font> and     preclinical and clinical <font color="blue">activities</font> by us or our <font color="blue">competitors</font>;           •   changes in our <font color="blue">existing corporate partnerships</font> or licensing     <font color="blue">arrangements</font>;           •   <font color="blue">establishment</font> of new corporate partnering or licensing <font color="blue">arrangements</font> by     us or our <font color="blue">competitors</font>;           •   our ability to <font color="blue">raise capital</font>;           •   <font color="blue">development</font>s or <font color="blue">disputes concerning</font> our <font color="blue">proprietary</font> rights;           •   issuance of new or changed analysts’ reports and <font color="blue">recommendations</font>     regarding us or our <font color="blue">competitors</font>;           •   share price and volume <font color="blue">fluctuations</font> attributable to <font color="blue">inconsistent</font>     <font color="blue">trading volume levels</font> of our shares;           •   changes in government <font color="blue">regulations</font>; and           •   economic or other <font color="blue">external factors</font></td>
    </tr>
    <tr>
      <td>Our existing <font color="blue">stockholders</font> have <font color="blue">significant</font> control of our <font color="blue">management</font> and     affairs</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">executive officers</font> and <font color="blue">directors</font> and holders of <font color="blue">greater than five</font>     percent of our outstanding voting stock, <font color="blue">together with</font> entities that may be     deemed <font color="blue">affiliates</font> of, or related to, <font color="blue">such persons</font> or entities, beneficially     owned <font color="blue">approximately</font> 41dtta8 percent of our <font color="blue">voting power as</font> of March 3, 2006</td>
    </tr>
    <tr>
      <td>As     a result, these <font color="blue">stockholders</font>, acting together, may be able to control our     <font color="blue">management</font> and affairs and matters requiring stockholder approval, including     the  election  of  <font color="blue">directors</font>  and  approval  of  <font color="blue">significant</font> corporate     <font color="blue">transactions</font>, such as mergers, <font color="blue">consolidations</font> or the sale of <font color="blue">substantially</font>     all of our assets</td>
    </tr>
    <tr>
      <td>Consequently, this <font color="blue">concentration</font> of <font color="blue">ownership may</font> have     the  effect  of delaying, deferring or preventing a change in control,     including a merger, consolidation, takeover or other business <font color="blue">combination</font>     <font color="blue">involving us</font> or discourage a <font color="blue">potential acquirer from</font> making a <font color="blue">tender offer</font>     or <font color="blue">otherwise attempting</font> to obtain control, which might affect the market     price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Anti-takeover <font color="blue">provisions could</font> make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to     acquire us</td>
    </tr>
    <tr>
      <td>In addition to the 1cmam500cmam000 shares of <font color="blue">Series A </font><font color="blue">convertible <font color="blue">preferred stock</font></font>     that  are  currently outstanding, as of November 4, 2005, our Board of     <font color="blue">Directors </font>has the authority to issue up to an <font color="blue">additional</font> 3cmam360cmam000 shares of     <font color="blue">preferred stock</font> and to determine the price, rights, preferences, privileges     and <font color="blue">restrictions</font>, including <font color="blue">voting rights</font>, of those <font color="blue">shares without</font> any     <font color="blue">further vote</font> or <font color="blue">action by</font> the <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights of the holders of     <font color="blue">common stock</font> may be subject to, and may be <font color="blue">adversely affected</font> by, the rights     of the holders of any <font color="blue">preferred stock</font> that may be issued in the future</td>
    </tr>
    <tr>
      <td>The     issuance of <font color="blue">preferred stock</font> may have the effect of delaying, deferring or     preventing a change of control of <font color="blue"><font color="blue">Seattle Genetics</font> </font>without further <font color="blue">action by</font>     the <font color="blue">stockholders</font> and <font color="blue">may adversely affect</font> the                                           27     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font>voting and other rights of the holders of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Further, certain     provisions of our <font color="blue">charter documents</font>, including provisions <font color="blue">eliminating</font> the     ability of <font color="blue">stockholders</font> to take <font color="blue">action by</font> written consent and limiting the     ability  of <font color="blue">stockholders</font> to <font color="blue">raise matters at</font> a meeting of <font color="blue">stockholders</font>     <font color="blue">without giving advance</font> notice, may have the effect of delaying or preventing     changes in control or <font color="blue">management</font> of <font color="blue">Seattle Genetics</font>, <font color="blue">which could</font> have an     adverse effect on the <font color="blue">market price</font> of our stock</td>
    </tr>
    <tr>
      <td>In addition, our charter     <font color="blue">documents provide</font> for a classified board, which may make it more <font color="blue">difficult</font>     for a <font color="blue">third party</font> to <font color="blue">gain control</font> of our <font color="blue">Board of Directors</font></td>
    </tr>
    <tr>
      <td>Similarly,     state anti-takeover laws in <font color="blue">Delaware and Washington </font>related to corporate     <font color="blue">takeovers may prevent</font> or delay a change of control of <font color="blue">Seattle Genetics</font></td>
    </tr>
  </tbody>
</table>